OptiPrep™ Mini-Review MV05

Purification and analysis of papillomaviruses

- OptiPrep™ is a sterile 60% (w/v) solution of iodixanol in water, density = 1.32 g/ml
- This Mini-Review principally provides (in Section 2) a bibliography of all those papers reporting the use of OptiPrep™ in the purification and analysis of papilloma virus and virus-like particles. Section 1 briefly summarizes the advantages of using OptiPrep™; the gradient strategy used for papillomavirus and the technical data that is available.

1. Technical background to the use of OptiPrep™

1a. Background

In all comparative studies between CsCl and iodixanol, the recovery of virus infectivity is much higher and the particle:infectivity ratio much lower when viruses are purified in iodixanol. Although sucrose is generally less deleterious to viral infectivity than CsCl, it can nevertheless also have serious effects on certain important aspects of viral function; in particular the loss of surface glycoproteins from enveloped viruses, particularly retroviruses, has been noted [1]. This may be related to its viscosity, which, in solutions of the same density, is much higher than that of iodixanol. Most iodixanol gradients can also be made isoosmotic over the entire density range.

Like CsCl, sucrose must be dialyzed before infectivity can be measured. In contrast both infectivity measurements using cultured cells and many add-on techniques can be performed without dialysis of iodixanol. Combined with the availability of OptiPrep™ as a sterile solution, this makes the use of OptiPrep™ for virus purification and assembly analysis much more convenient than the use of either CsCl or sucrose. The only analytical technique for which removal of the iodixanol is essential is electron microscopy. Consequently iodixanol is being increasingly used for the purification of papillomavirus particles from lysed cultured cells.

1b. Gradient strategy

Buck et al [2] observed that papillomavirus vector stocks could be purified by an iodixanol gradient centrifugation procedure that was substantially more effective than the standard CsCl gradient purification. The methodology developed [2] has been used more or less unchanged in all subsequent studies and has been found to be effective for human, bovine and cotton-tail rabbit viruses. A continuous gradient is usually generated from equal volumes of 27%, 33% and 39% (w/v) iodixanol allowed to diffuse for 3-4 h at room temperature, after which the clarified sample is laid on top. Although the continuous gradient might be prepared from 27% and 39% iodixanol using a two-chamber gradient maker, use of the latter is technically more difficult with these small volume gradients. The separation of the L1 protein from both DNA-containing and empty virus-like particles after 234,000 *g* for 3.5 h at 16°C is considered to be part buoyant density and part sedimentation velocity [2], so top-loading of the sample cannot be replaced by other frequently-used strategies such as bottom-loading of the sample or the use of self-generated gradients.

1c. References (to Sections 1a and 1b)

1. Palker, T.J. (1990) *Mapping of epitopes on human T-cell leukemia virus type 1 envelope glycoprotein* In: Human Retrovirology: HTLV (ed. Blattner, W.A.) Raven Press, NY, pp 435-445
2. Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T. (2004) *Efficient intracellular assembly of papillomaviral vectors* J. Virol., **78**, 751-757

- The gradient protocol for the purification of isolation of papillomavirus particles (**Application Sheet V10**) may be accessed from the OptiPrep™ Applications flash-drive or from the following website: www.axis-shield-density-gradient-media.com, click on "Methodology" then "Viruses" to open up the Virus Index. Other OptiPrep™ Application Sheets on the preparation and harvesting of gradients may also be accessed from the top of the Index.

2. Bibliography

- This bibliography provides a comprehensive reference list of all the papers reporting the use of OptiPrep™ for papillomavirus purification, published before the end of January 2017.
- The references are divided alphabetically into **"Research topic" sections** and **subsections.**
- All references are listed alphabetically according to **First Author.**
- The vast majority of published papers describe studies on human papillomavirus (not flagged); those studies on bovine **(B)**, canine **(C)**, cotton-tailed rabbit **(CTR)**, equine **(E),** Macaques **(MQ)** and mouse **(M)** are indicated as shown. In many cases these flagged papers will also include work on the human virus.

1. B-cell anergy reversal

Chackerian, B., Durfee, M.R. and Schiller, J.T. (2008) *Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model* J. Immunol., **180**, 5816-5825 **(M)**

2. Baculoviral vectors

Cho, H., Lee, H-J., Heo, Y-K., Cho, Y., Gwon, Y-D., Kim, M-G., Park, K.H., Oh, Y-K. and Kim, Y.B. (2014) *Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine* PLoS One, **9**: e95961

Lee, H-J., Hur, Y-K., Cho, Y-D., Kim, M-G., Lee, H-T., Oh, Y-K. and Kim, Y.B. (2012) *Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs* PLoS One, **7**: e50296

Lee, H-J., Cho, H., Kim, M-G., Heo, Y-K., Cho, Y., Gwon, Y-D., Park, K.H., Jin, H., Kim, J., Oh, Y-K. and Kim, Y.B. (2015) *Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge* PLoS One, **10**: e0119408

3. Capsids and capsid protein

3-1. Capsid assembly

Day, P.M., Thompson, C.D., Pang, Y.Y., Lowy, D.R. and Schiller, J.T. (2015) *Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids* Papillomavirus Res. **1**, 74–89

3-2. DNA, separation from

Bzhalava, D., Johansson, H., Ekström, J., Faust, H., Möller, B., Eklund, C., Nordin, P., Stenquist, B., Paoli, J., Persson, B., Forslund, O. and Dillner, J. (2013) *Unbiased approach for virus detection in skin lesions* PLoS One, **8**: e65953

3-3. Dynein interacting domains

Florin, L., Becker, K.A., Lambert, C., Nowak, T., Sapp, C., Strand, D., Streeck, R.E. and Sapp, M. (2006) *Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2* J. Virol., **80**, 6691-6696

3-4. L1 capsid protein

Bienkowska-Haba, M., Williams, C., Kim, S.M., Garcea, R.L. and Sapp, M. (2012) *Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry* J. Virol., **86**, 9875-9887

Ishii, Y., Kondo, K., Matsumoto, T., Tanaka, K., Shinkai-Ouchi, F., Hagiwara, K. and Kanda, T. (2007) *Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1* Virol. J., **4:**110

Mistry, N., Wibom, C. and Evander, M. (2008) *Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism* Virol. J., **5**:118

Ryndock, E.J., Conway, M.J., Alam, S., Gul, S., Murad, S., Christensen, N.D. and Meyers, C. (2014) *Roles for human papillomavirus type 16 L1 cysteine residues 161, 229, and 379 in genome encapsidation and capsid stability* PLoS One, **9**: e99488

3-5. Maturation

Buck, C.B., Thompson, C.D., Pang, Y-Y-s., Lowy, D.R. and Schiller, J.T. (2005) *Maturation of papillomavirus capsids* J. Virol., **79**, 2839-2846 **(B)**

Cardone, G., Moyer, A.L., Cheng, N., Thompson, C.D., Dvoretzky, I., Lowy, D.R., Schiller, J.T., Steven, A.C., Buck, C.B. and Trus, B.L. (2014) *Maturation of the human papillomavirus 16 capsid* mBio, **5**: e01104-14

Conway, M.J., Cruz, L., Alam, S., Christensen, N.D. and Meyers, C. (2011) *Differentiation-dependent interpentameric disulfide bond stabilizes native human papillomavirus type 16* PLoS One, **6**: e22427

3-6. Neutralization-sensitive epitopes

Culp, T.D., Spatz, C.M., Reed, C.A. and Christensen, N.D. (2007) *Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments and scFv specific for L1 epitopes on the capsid of infectious* HPV particles Virology, **361**, 435-446

3-7. Tumour cell binding

Kines, R.C., Cerio, R.J., Roberts, J.N., Thompson, C.D., de Los Pinos, E., Lowy, D.R. and Schiller, J.T. (2016) *Human papillomavirus capsids preferentially bind and infect tumor cells* Int. J. Cancer, **138**, 901–911

4. Cell entry/targeting

4-1. Autophagy inhibition

Surviladze, Z., Sterk, R.T., DeHaro, S.A. and Ozbun, M.A. (2013) *Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy* J. Virol., **87**, 2508–2517

4-2. Clathrin/caveolin

Spoden, G., Freitag, K., Husmann, M., Boller, K., Sapp, M., Lambert, C. and Florin, L. (2008) *Clathrin- and caveolin-independent entry of human papillomavirus type 16 - involvement of tetraspanin-enriched microdomains (TEMs)* PLoS One, **3**:e3313

4-3. Cyclophilin receptors

Bienkowska-Haba, M., Patel, H.D. and Sapp, M. (2009) *Target cell cyclophilins facilitate human papillomavirus type 16 infection* PLoS Pathog., **5**:e1000524 **(B)**

4-4. Cysteine proteases

Dabydeen, S.A. and Meneses, P.I. (2009) *The role of NH_4Cl and cysteine proteases in human papillomavirus type 16 infection* Virol. J., **6**:109

4-5. Dynamin inhibition

Abban, C.Y., Bradbury, N.A. and Meneses, P.I. (2008) *HPV16 and BPV1 infection can be blocked by the dynamin inhibitor dynasore* Am. J. Therapeut., **15**, 304-311 **(B)**

4-6. Dynein light chain requirement

Schneider, M.A., Spoden, G.A., Florin, L. and Lambert, C. (2011) *Identification of the dynein light chains required for human papillomavirus infection* Cell. Microbiol., **13**, 32–46

4-7. Focal adhesion kinase activation

Abban, C.Y. and Meneses, P.I. (2010) *Usage of heparan sulfate, integrins, and FAK in HPV16 infection* Virology **403**, 1–16

4-8. Gene delivery vectors

Cerqueira, C., Thompson, C.D., Day, P.M., Pang, Y-Y.S., Lowy, D.R. and Schiller, J.T. (2017) *Efficient production of papillomavirus gene delivery vectors in defined in vitro reactions* Mol. Ther. Meth. Clin. Dev., **5**, 165-179

4-9. Heparan sulphate receptors

Abban, C.Y. and Meneses, P.I. (2010) *Usage of heparan sulfate, integrins, and FAK in HPV16 infection* Virology **403**, 1–16

Day, P.M., Lowy, D.R. and Schiller, J.T. (2008) *Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids* J. Virol., **82**, 12565-12568

Donalisio, M., Rusnati, M., Civra, A., Bugatti, A., Allemand, D., Pirri, G., Giuliani, A., Landolfo, S. and Lembo, D. (2010) *Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses* Anitmicrob. Agents Chemother., **54**, 4290-4299

Johnson, K.M., Kines, R.C., Roberts, J.N., Lowy, D.R., Schiller, J.T. and Day, P.M. (2009) *Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus* J. Virol., **83**, 2067-2074

Knappe, M., Bodevin, S., Selinka, H-C., Spillman, D., Streeck, R.E., Chen, X.S., Lindahl, U. and Sapp, M. (2007) *Surface-exposed amino acid residues of HPV16L1 protein mediating interaction with cell surface heparan sulfate* J. Biol. Chem., **282**, 27913-27922

Selinka, H-C., Florin, L., Patel, H.D., Freitag, K., Schmidtke, M., Makarov, V.A. and Sapp, M. (2007) *Inhibition of transfer to secondary receptors by heparin sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus* J. Virol., **81**, 10970-10980

4-10. Inhibition by thio-reactive agents

Ishii, Y., Kondo, K., Matsumoto, T., Tanaka, K., Shinkai-Ouchi, F., Hagiwara, K. and Kanda, T. (2007) *Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1* Virol. J., **4:**110

4-11. Laminin-5 binding

Culp, T.D., Budgeon, L.R., Marinkovich, M.P., Meneguzzi, G. and Christensen, N.D. (2006) *Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells* J. Virol., **80**, 8940-8950

4-12. L1/L2 protein interactions

Buck, C.B., Cheng, N., Thompson, C.D., Lowy, D.R., Steven, A.C., Schiller, J.T. and Trus, B.L. (2008) *Arrangement of L2 within the papillomavirus capsid* J. Virol., **82**, 5190-5197
Knappe, M., Bodevin, S., Selinka, H-C., Spillman, D., Streeck, R.E., Chen, X.S., Lindahl, U. and Sapp, M. (2007) *Surface-exposed amino acid residues of HPV16L1 protein mediating interaction with cell surface heparan sulfate* J. Biol. Chem., **282**, 27913-27922

4-13. Microtubules, L2 interaction with

Schneider, M.A., Spoden, G.A., Florin, L. and Lambert, C. (2011) *Identification of the dynein light chains required for human papillomavirus infection* Cell. Microbiol., **13**, 32–46

4-14. Phsophatidylinositol-3 kinase

Surviladze, Z., Sterk, R.T., DeHaro, S.A. and Ozbun, M.A. (2013) *Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy* J. Virol., **87**, 2508–2517

4-15. PML expression

Day, P.M., Baker, C.C., Lowy, D.R. and Schiller, J.T. (2004) *Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression* Proc. Natl. Acad. Sci. USA, **101**, 14252-14257 **(B)**

4-16. γ-Secretase requirement

Huang, H-S., Buck, C.B. and Lambert, P.F. (2010) *Inhibition of gamma secretase blocks HPV infection* Virology **407**, 391–396
Karanam, B., Peng, S., Li, T., Buck, C., Day, P.M. and Roden, R.B.S. (2010) *Papillomavirus infection requires γ secretase* J. Virol., **84**, 10661–10670 **(CTR)**

4-17. Tetraspannin-enriched domains

Scheffer, K.D., Gawlitza, A., Spoden, G.A., Zhang, X.A., Lambert, C., Berditchevski, F. and Florina, L. (2013) *Tetraspanin CD151 mediates papillomavirus type 16 endocytosis* J. Virol., **87**, 3435–3446
Spoden, G., Freitag, K., Husmann, M., Boller, K., Sapp, M., Lambert, C. and Florin, L. (2008) *Clathrin- and caveolin-independent entry of human papillomavirus type 16 - involvement of tetraspanin-enriched microdomains (TEMs)* PLoS One, **3**:e3313

5. Epithelial cell, expression in

Israr, M., Biryukov, J., Ryndock, E.J., Alam, S. and Meyers, C. (2016) *Comparison of human papilloma-virus type16 replication in tonsil and foreskin epithelia* Virology, **499**, 82–90

6. Gene expression

Berg, M., Gambhira, R., Siracusa, M., Hoiczyk, E., Roden, R. and Ketner, G. (2007) *HPV16L1 capsid protein expressed from viable adenovirus recombinant elicits neutralizing antibody in mice* Vaccine, **25**, 3501-3510

7. Genome

7-1. Amplification

Culp, T.D., Cladel, N.M., Balogh, K.K., Budgeon, L.R., Mejia, A.F. and Christensen, N.D. (2006) *Papillomavirus particles assembled in 293TT cells are infectious in vivo* J. Virol., **80**, 11381-11384 **(CTR)**

7-2. Encapsidation

Pyeon, D., Lambert, P.F. and Ahlquist, P. (2005) *Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation* Proc. Natl. Acad. Sci. USA, **102**, 9311-9316

7-3. Packaging

Cerqueira, C., Pang, Y-Y.S., Day, P.M., Thompson, C.D., Buck, C.B., Lowy, D.R. and Schiller, J.T. (2016) *A cell-free assembly system for generating infectious human papillomavirus 16 capsids implicates a size discrimination mechanism for preferential viral genome packaging* J. Virol., **90**, 1096-1107

8. Immunogenicity

Kwag, H-L., Kim, H.J., Chang, D.Y. and Kim, H-J. (2012) *The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae* J. Microbiol., **50**, 813-820

Lee, H-J., Hur, Y-K., Cho, Y-D., Kim, M-G., Lee, H-T., Oh, Y-K. and Kim, Y.B. (2012) *Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs* PLoS One, **7**: e50296

9. Infection

9-1. Anti-L1 antibodies

Hu, J., Budgeon, L.R., Cladel, N.M., Culp, T.A., Balogh, K.K. and Christensen, N.D. (2007) *Detection of L1, infectious virions and anti-L1 antibody in domestic rabbits infected with cottontail rabbit papillomavirus* J. Gen. Virol., **88**, 3286-3293 **(CTR)**

9-2. Antivirals

Huang, H-S., Pyeon, D., Pearce, S.M., Lank, S.M., Griffin, L.M., Ahlquist, P., Lambert, P.F. (2012) *Novel antivirals inhibit early steps in HPV infection* Antiviral Res., **93**, 280–287

Theisen, L.L., Erdelmeier, C.A.J., Spoden, G.A., Boukhallouk, F., Sausy, A., Florin, L. and Muller, C.P. (2014) *Tannins from Hamamelis virginiana bark extract:characterization and improvement of the antiviral efficacy against influenza A virus and human papillomavirus* PLoS One, **9**: e88062

9-3. Cell cycle progression requirement

Pyeon, D., Pearce, S.M., Lank, S.M., Ahlquist, P. and Lambert, P.F. (2009) *Establishment of human papillomavirus infection requires cell cycle progression* PLoS Pathog., **5**:e1000318

9-4. Dopachrome tautomerase

Aksoy, P. and Meneses, P.I. (2017) *The role of DCT in HPV16 infection of HaCaTs* PLoS One **12**: e0170158

9-5. L2 Cysteine residues

Gambhira, R., Jagu, S., Karanam, B., Day, P.M. and Roden, R. (2009) *Role of L2 cysteines in papillomavirus infection and neutralization* Virol. J., **6**: 176 **(B)**

9-6. Heparan sulphate

Cagno, V., Donalisio, M., Bugatti, A., Civra, A., Cavalli, R., Ranucci, E., Ferruti, P., Rusnati, M. and Lembo, D. (2015) *The agmatine-containing poly(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses* Antimicrob. Agents Chemother., **59**, 5250-5259

Huang, H-S. and Lambert, P.F. (2012) *Use of an in vivo animal model for assessing the role of integrin $\alpha_6\beta_4$ and Syndecan-1 in early steps in papillomavirus infection* Virology, **433**, 395–400

Johnson, K.M., Kines, R.C., Roberts, J.N., Lowy, D.R., Schiller, J.T. and Day, P.M. (2009) *Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus* J. Virol., **83**, 2067-2074

Kines, R.C., Cerio, R.J., Roberts, J.N., Thompson, C.D., de Los Pinos, E., Lowy, D.R. and Schiller, J.T. (2016) *Human papillomavirus capsids preferentially bind and infect tumor cells* Int. J. Cancer, **138**, 901–911

Kumar, A., Jacob, T., Abban, C.Y. and Meneses, P.I. (2014) *Intermediate heparan sulfate binding during HPV-16 infection in HaCaTs* Am. J. Therapeut., **21**, 331–342

Lembo, D., Donalisio, M., Laine, C., Cagno, V., Civra, A., Bianchini, E.P., Zeghbib, N. and Bouchemal, K. (2014) *Auto-associative heparin nanoassemblies: A biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV* Eur. J. Pharm. Biopharm., **88,** 275–282

9-7. Integrins

Aksoy, P., Abban, C.Y., Kiyashka, E., Qiang, W. and Meneses, P.I. (2014) *HPV16 infection of HaCaTs is dependenton β4 integrin, and α6 integrin processing* Virology, **449**, 45–52

Huang, H-S. and Lambert, P.F. (2012) *Use of an in vivo animal model for assessing the role of integrin $\alpha_6\beta_4$ and Syndecan-1 in early steps in papillomavirus infection* Virology, **433**, 395–400

9-8. Optical imaging

Kines, R.C., Kobayashi, H., Choyke, P.L. and Bernardo, M.L. (2013) *Optical imaging of HPV infection in a murine model* In Mol. Dermatol: Methods and Protocols (ed. Has, C. and Sitaru, C.) Springer Science+Business Media, LLC, pp 141-150

9-9. Restriction factors

Warren, C.J., Xu, T., Guo, K., Griffin, L.M., Westrich, J.A., Lee, D., Lambert, P.F,, Santiago, M.L. and Pyeona, D. (2015) *APOBEC3A functions as a restriction factor of human papillomavirus* J. Virol., 89, 688-702

9-10. γ-Secretase requirement

Huang, H-S., Buck, C.B. and Lambert, P.F. (2010) *Inhibition of gamma secretase blocks HPV infection* Virology **407**, 391–396

Karanam, B., Peng, S., Li, T., Buck, C., Day, P.M. and Roden, R.B.S. (2010) *Papillomavirus infection requires γ secretase* J. Virol., **84**, 10661–10670 **(CTR)**

9-11. Single particle tracking

Ewers, H. and Schelhaas, M. (2012) *Analysis of virus entry and cellular membrane dynamics by single particle tracking* Methods Enzymol., **506**, 63-80

9-12. Skin/vaginal/wart lesions

Bzhalava, D., Johansson, H., Ekström, J., Faust, H., Möller, B., Eklund, C., Nordin, P., Stenquist, B., Paoli, J., Persson, B., Forslund, O. and Dillner, J. (2013) *Unbiased approach for virus detection in skin lesions* PLoS One, **8**: e65953

Chu, T-Y., Chang, Y-C. and Ding, D.C. (2013) *Cervicovaginal secretions protect from human papillomavirus infection: Effects of vaginal douching* Taiwan. J. Obstet. Gynecol., **52**, 241-245

Çuburu, N., Cerio, R.J., Thompson, C.D. and Day, P.M. (2015) *Mouse model of cervicovaginal papillomavirus infection* In Cervical Cancer: Methods and Protocols, Methods in Molecular Biology, vol. 1249 (eds. Keppler, D. and Lin, A.W. Springer Science+Business Media New York, pp 365-379 **(M)**

Handisurya, A., Day, P.M., Thompson, C.D., Buck, C.B., Kwak, K., Roden, R.B.S., Lowy, D.R. and Schiller, J.T. (2012) *Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species* Virology, **433**, 385–394 **(M)**

Meyers, J.M., Uberoi, A., Grace, M., Lambert, P.F. and Munger, K. (2017) *Cutaneous HPV8 and MmuPV1 E6 proteins target the NOTCH and TGF-β tumor suppressors to inhibit differentiation and sustain keratinocyte proliferation* PLoS Pathog., **13**: e1006171 **(M)**

Roberts, J.N., Kines, R.C., Katki, H.A., Lowy, D.R. and Schiller, J.T. (2011) *Effect of pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model* J. Natl. Cancer Inst., **103**, 737–743 **(MQ)**

Vinzón, S.E., Braspenning-Wesch, I., Müller, M., Geissler, E.K., Nindl, I., Gröne, H-J., Schäfer, K. and Rösl, F. (2014) *Protective vaccination against papillomavirus-induced skin tumors under immuno-competent and immunosuppressive conditions: a preclinical study using a natural outbred animal model* PLoS Pathog., **10**: e1003924 **(M)**

Xue, X-Y., Majerciak, V., Uberoi, A., Kim, B-H., Gotte, D., Chen, X., Cam, M., Lambert, P.F. and Zheng, Z-M. (2017) *The full transcription map of mouse papillomavirus type 1 (MmuPV1) in mouse wart tissue* PloS Pathog. **13**: e1006715 **(M)**

9-13. Syndecan-1

Huang, H-S. and Lambert, P.F. (2012) *Use of an in vivo animal model for assessing the role of integrin $\alpha_6\beta_4$ and Syndecan-1 in early steps in papillomavirus infection* Virology, **433**, 395–400

10. Infection inhibition

10-1. Carrageenen

Buck, C.B., Thompson, C.D., Roberts, J.N., Müller, M., Lowy, D.R. and Schiller, J.T. (2007) *Carrageenan is a potent inhibitor of papillomavirus function* Plos Pathog., **2**:e69

Novetsky, A.P., Keller, M.J., Gradissimo, A., Chen, Z., Morgan, S.L., Xue, X., Strickler, H.D., Fernández-Romero, J.A., Burk, R. and Einstein, M.H. (2016) *In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel* Gynecol. Oncol., **143**, 313–318

10-2. Cholesterol derivatives

Civra, A., Cagno, V., Donalisio, M., Biasi, F., Leonarduzzi, G., Poli, G. and Lembo, D. (2014) *Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol* Sci. Rep., 4: 7487

10-3. α-Defensins

Buck, C.B., Day, P.M., Thompson, C.D., Lubkowski, J., Lu, W., Lowy, D.R. and Schiller, J.T. (2006) *Human α-defensins block papillomavirus infection* Proc. Natl. Acad. Sci. USA, **103**, 1516-1521

Gounder, A.P., Wiens, M.E., Wilson, S.S., Lu, W. and Smith, J.G. (2012) *Critical determinants of human α-defensin 5 activity against non-enveloped viruses* J. Biol. Chem., **287**, 24554–24562

Wiens, M.E. and Smith, J.G. (2015) *Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection* J. Virol., **89**, 2866-2874

Wiens, M.E. and Smith, J.G. (2017) *α-Defensin HD5 inhibits human papillomavirus 16 infection via capsid stabilization and redirection to the lysosome* mBio, **8**: e02304-16

10-4. *E. coli* sulphated polysaccharides

Lembo, D., Donalisio, M., Rusnati, M., Bugatti, A., Cornaglia, M., Cappello, P., Giovarelli, M., Oreste, P. and Landolfo, S. (2008) *Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus* Antimicrob. Agents Chemother., **52,** 1374-1381

10-5. Genome, nuclear transport block

Ishii, Y., Tanaka, K., Kondo, K., Takeuchi, T., Mori, S. and Kanda, T. (2010) *Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody* Virology **406**, 181–188

10-6. Heparan sulphate binding

Cagno, V., Donalisio, M., Bugatti, A., Civra, A., Cavalli, R., Ranucci, E., Ferruti, P., Rusnati, M. and Lembo, D. (2015) *The agmatine-containing poly(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses* Antimicrob. Agents Chemother., **59**, 5250-5259

Donalisio, M., Rusnati, M., Civra, A., Bugatti, A., Allemand, D., Pirri, G., Giuliani, A., Landolfo, S. and Lembo, D. (2010) *Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses* Anitmicrob. Agents Chemother., **54**, 4290-4299

10-7. High affinity ligands

Mauro, N., Ferruti, P., Ranucci, E., Manfredi, A., Berzi, A., Clerici, M., Cagno, V., Lembo, D., Palmioli, A. and Sattin, S. (2016) *Linear biocompatible glycopolyamidoamines as dual action mode virus infection inhibitors with potential as broad-spectrum microbicides for sexually transmitted diseases* Sci. Rep., **6**: 33393

10-8. Interferon

Day, P.M., Thompson, C.D., Lowy, D.R. and Schiller, J.T. (2017) *Interferon gamma prevents infectious entry of human papillomavirus 16 via an L2-dependent mechanism* J. Virol., **91**: e00168-17

10-9. L1/L2 antibody, comparison of

Day, P.M., Kines, R.C., Thompson, C.D., Jagu, S., Roden, R.B., Lowy, D.R. and Schiller, J.T. (2010) *In vivo mechanisms of vaccine-induced protection against HPV infection* Cell Host Microbe, **8**, 260–270

Day, P.M., Thompson, C.D., Lowy, D.R. and Schiller, J.T. (2017) *Interferon gamma prevents infectious entry of human papillomavirus 16 via an L2-dependent mechanism* J. Virol., **91**: e00168-17

10-10. Mucins

Lieleg, O., Lieleg, C., Bloom, J., Buck, C.B. and Ribbeck, K. (2012) *Mucin biopolymers as broad-spectrum antiviral agents* Biomacromolecules, **13**, 1724−1732

11. Infectious virus production

Müller, K.H., Spoden, G.A., Scheffer, K.D., Brunnhöfer, R., De Brabander, J.K., Maier, M.E., Florin, L. and Muller, C.P. (2014) *Inhibition by cellular vacuolar ATPase impairs human papillomavirus uncoating and infection* Antimicrob. Agents Chemother., **58**, 2905–2911

Pyeon, D., Lambert, P.F. and Ahlquist, P. (2005) *Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation* Proc. Natl. Acad. Sci. USA, **102**, 9311-9316

12. Intracellular assembly

12-1. L1/L2 proteins

Bissa, M., Zanotto, C., Pacchioni, S., Volonté, L., Venuti, A., Lembo, D., De Giuli Morghen, C. and Radaelli, A. (2015) *The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response* Antiviral Res., **116**, 67–75

Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T. (2004) *Efficient intracellular assembly of Papillomaviral vectors* J. Virol., **78**, 751-757 **(B)**

Buck, C.B., Cheng, N., Thompson, C.D., Lowy, D.R., Steven, A.C., Schiller, J.T. and Trus, B.L. (2008) *Arrangement of L2 within the papillomavirus capsid* J. Virol., **82**, 5190-5197

Conway, M.J. and Meyers, C. (2009) *Replication and assembly of human papillomaviruses* Dent. Res., **88**, 307-317 **(CTR)**

Day, P.M., Thompson, C.D., Lowy, D.R. and Schiller, J.T. (2017) *Interferon gamma prevents infectious entry of human papillomavirus 16 via an L2-dependent mechanism* J. Virol., **91**: e00168-17

12-2. L2 cysteine residues

Conway, M.J., Alam, S., Christensen, N.D. and Meyers, C. (2009) *Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines* Virology **393**, 295–303

Gambhira, R., Jagu, S., Karanam, B., Day, P.M. and Roden, R. (2009) *Role of L2 cysteines in papillomavirus infection and neutralization* Virol. J., **6**: 176 **(B)**

12-3. Redox gradient dependence

Conway, M.J., Alam, S., Ryndock, E.J., Cruz, L., Christensen, N.D., Roden, R.B.S. and Meyers, C. (2009) *Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions* J. Virol., **83**, 10515-10526

13. Intracellular trafficking:

13-1. Cysteine proteases

Dabydeen, S.A. and Meneses, P.I. (2009) *The role of NH_4Cl and cysteine proteases in human papillomavirus type 16 infection* Virol. J., **6**:109

Dynein interacting domain

Florin, L., Becker, K.A., Lambert, C., Nowak, T., Sapp, C., Strand, D., Streeck, R.E. and Sapp, M. (2006) *Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2* J. Virol., **80**, 6691-6696

13-2. Endosomal trafficking

Gräßel, L., Fast, L.A., Scheffer, K.D., Boukhallouk, F., Spoden, G.A., Tenzer, S., Boller, K., Bago, R., Rajesh, S. et al (2016) *The CD63-syntenin-1 complex controls post-endocytic trafficking of oncogenic human papillomaviruses* Sci. Rep., **6**: 32337

Popa, A., Zhang, W., Harrison, M.S., Goodner, K., Kazakov, T., Goodwin, E.C., Lipovsky, A., Burd, C.G. and DiMaio, D. (2015) *Direct binding of retromer to human papillomavirus type 16 minor capsid protein L2 mediates endosome exit during viral infection* PLoS Pathog., **11**: e1004699

13-3. Genome, nuclear transport block

Ishii, Y., Tanaka, K., Kondo, K., Takeuchi, T., Mori, S. and Kanda, T. (2010) *Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody* Virology **406**, 181–188

13-4. Inhibition by thio-reactive agents

Ishii, Y., Kondo, K., Matsumoto, T., Tanaka, K., Shinkai-Ouchi, F., Hagiwara, K. and Kanda, T. (2007) *Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1* Virol. J., **4:**110

13-5. L2 capsid protein

Kondo, K., Ishii, Y., Mori, S., Shimabukuro, S., Yoshikawa, H. and Kanda, T. (2009) *Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions* Virology **394**, 259−265

Mamoor, S., Onder, Z., Karanam, B., Kwak, K., Bordeaux, J., Crosby, L., Roden, R.B.S. and Moroianu, J. (2012) *The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic* Virology, **422**, 413–424

13-6. PML expression

Day, P.M., Baker, C.C., Lowy, D.R. and Schiller, J.T. (2004) *Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression* Proc. Natl. Acad. Sci. USA, **101**, 14252-14257 **(B)**

13-7. Polyethyleninimes

Spoden, G.A., Besold, K., Krauter, S., Plachter, B., Hanik, N., Kilbinger, A.F.M., Lambert, C. and Florina, L. (2012) *Polyethylenimine is a strong inhibitor of human papillomavirus and cytomegalovirus infection* Antimicrob. Agents Chemother., **56**, 75-82

14. Keratinocyte/expression in/interactions

Brendle, S.A. and Christensen, N.D. (2015) *HPV binding assay to Laminin-332/Integrin α6β4 on human keratinocytes* In Cervical Cancer: Methods and Protocols, Methods in Molecular Biology, vol. 1249 (eds. Keppler, D. and Lin, A.W. Springer Science+Business Media New York, pp 53-66

McKinney, C.C., Kim, M.J., Chen, D. and McBride, A.A. (2016) *Brd4 activates early viral transcription upon human papillomavirus 18 infection of primary keratinocytes* mBio, **7:** e01644-16

Tao, L., Pavlova, S.I., Gasparovich, S.R., Jin, L. and Schwartz, J. (2015) *Alcohol metabolism by oral Streptococci and interaction with human papillomavirus leads to malignant transformation of oral keratinocytes* In Advances in Experimental Medicine and Biology, **815** Biological Basis of Alcohol-Induced Cancer. (ed. Vasiliou, V. et al), Springer International Publishing Switzerland pp 239-264

Van Doorslaer, K., Porter, S., McKinney, C., Stepp, W.H. and McBride, A.A. (2016) *Novel recombinant papillomavirus genomes expressing selectable genes* Sci. Rep., **6**: 37782

15. Langerhans cell activation

Da Silva, D.M., Movius, C.A., Raff, A.B., Brand, H.E., Skeate, J.G., Wong, M.K. and Kast, W.M. (2014) *Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a μ genotype* Virology, **452-453**, 279–286

16. Methodology

Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T. (2004) *Efficient intracellular assembly of Papillomaviral vectors* J. Virol., **78**, 751-757 **(B)**

Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T (2005) *Generation of HPV pseudovirions using transfection and their use in neutralization assays* Methods Mol. Med., **119**, 445-462

17. Neutralization assays

Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T (2005) *Generation of HPV pseudovirions using transfection and their use in neutralization assays* Methods Mol. Med., **119**, 445-462

Lamprecht, R.L., Kennedy, P., Huddy, S.M., Bethke, S., Hendrikse, M., Hitzeroth, I.I. and Rybicki, E.P. (2016) *Production of human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralization assays in mammalian cells* Sci. Rep., **6**: 20431

Pastrana, D.V., Buck, C.B., Pang, Y-Y. S., Thompson, C.D., Castle, P.E., Fitzgerald, P.C., Kjaer, S.K., Lowy, D.R. and Schiller, J.T. (2004) *Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18* Virology, **321**, 205-216

Sehr, P., Rubio, I., Seitz, H., Putzker, K., Ribeiro-Müller, L., Pawlita, M. and Müller, M. (2013) *High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses* PLoS One, **8**: e75677

Steele, J., Collins, S., Wen, K., Ryan, G., Constandinou-Williams, C. and Woodman, C.B.J. (2008) *Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay* Clin. Vaccine Immunol., **15,** 1387-1390 **(B)**

18. Neutralizing antibodies

18-1. Capsid protein

Culp, T.D., Spatz, C.M., Reed, C.A. and Christensen, N.D. (2007) Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments and scFv specific for L1 epitopes on the capsid of infectious HPV particles Virology, **361**, 435-446

18-2. L1 epitopes

Carter, J.J., Wipf, G.C., Madelaine, M.M., Schwartz, S.M., Koutsky, L.A. and Galloway, D.A. (2006) *Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera* J. Virol., **80**, 4664-4672

Roth, S.D., Sapp, M., Streeck, R.E. and Selinka, H-C. (2006) *Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33* Virol. J., **3:83**

18-3. L2 epitopes

Kondo, K., Ishii, Y., Ochi, H., Matsumoto, T., Yoshikawa, H. and Kanda, T. (2007) *Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region* Virology, **358**, 266-272

Pastrana, D.V., Gambhira, R., Buck, C.B., Pang, Y-Y.S., Thompson, C.D., Culp, T.D., Christensen, N.D., Lowy, D.R., Schiller, J.T. and Roden, R.B.S. (2005) *Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sea to the amino terminus of L2* Virology, **337**, 365-372 **(B, CTR)**

Seitz, H., Schmitt, M., Böhmer, G., Kopp-Schneider, A. and Müller, M. (2013) *Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2* Int. J. Cancer, **132**, E139–E148

19. Oropharyngeal cancer

Conway, M.J. and Meyers, C. (2009) *Replication and assembly of human papillomaviruses* Dent. Res., **88**, 307-317 **(CTR)**

20. Ovarian cancer therapy

Hung, C-F., Chiang, A.J., Tsai, H-H., Pomper, M.G., Kang, T.H., Roden, R.R. and Wu, T-C. (2012) *Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene* PLoS One, **7**: e40983

Kines, R.C., Cerio, R.J., Roberts, J.N., Thompson, C.D., de Los Pinos, E., Lowy, D.R. and Schiller, J.T. (2016) *Human papillomavirus capsids preferentially bind and infect tumor cells* Int. J. Cancer, **138**, 901–911

21. *Pichia pastoris* infection

Gupta, G., Glueck, R. and Rishi, N. (2017) *Physicochemical characterization and immunological properties of Pichia pastoris based HPV16L1 and 18L1 virus like particles* Biologicals, **46**, 11-22

Rao, N.H., Babu, P.B., Rajendra, L.., Sriraman, R., Pang, Y-Y.S., Schiller, J.T. and Srinivasan, V.A. (2011) *Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles* Vaccine, **29**, 7326– 7334

22. Plants, production in

Lamprecht, R.L., Kennedy, P., Huddy, S.M., Bethke, S., Hendrikse, M., Hitzeroth, I.I. and Rybicki, E.P. (2016) *Production of human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralization assays in mammalian cells* Sci. Rep., **6**: 20431

23. Proteoglycans

Huang, H-S. and Lambert, P.F. (2012) *Use of an in vivo animal model for assessing the role of integrin $\alpha_6\beta_4$ and Syndecan-1 in early steps in papillomavirus infection* Virology, **433**, 395–400

24. Recombinant viruses

Van Doorslaer, K., Porter, S., McKinney, C., Stepp, W.H. and McBride, A.A. (2016) *Novel recombinant papillomavirus genomes expressing selectable genes* Sci. Rep., **6**: 37782

25 Serology

Bissett, S.L., Wilkinson, D., Tettmar, K.I., Jones, N., Stanford, E., Panicker, G., Faust, H., Borrow, R., Soldan, K., Unger, E.R., Dillner, J., Minor, P. and Beddows, S. (2012) *Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology* Clin. Vaccin. Immunol., **19** 449–451

Dillner, J. and Zhou, T. (2007) Meeting report of the WHO workshop and practical course on human papillomavirus (HPV) genotyping and HPV16/18 serology, Lusanne, Switzerland, June 2007

Faust, H., Knekt, P., Forslund, O. and Dillner, J. (2010) *Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparincoated beads* J. Gen. Virol., **91**, 1840–1848

26. SNARE/Syntaxin

Culp, T.D., Budgeon, L.R., Marinkovich, M.P., Meneguzzi, G. and Christensen, N.D. (2006) *Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells* J. Virol., **80**, 8940-8950

Laniosz, V., Nguyen, K.C. and Meneses, P.I. (2007) *Bovine papillomavirus type 1 infection is mediated by SNARE Syntaxin 18* J. Virol., **81**, 7435-7448 **(B)**

27. Sublingual immunization

Lee, H-J., Cho, H., Kim, M-G., Heo, Y-K., Cho, Y., Gwon, Y-D., Park, K.H., Jin, H., Kim, J., Oh, Y-K. and Kim, Y.B. (2015) *Sublingual immunization of trivalent human papillomavirus DNA vaccine in baculovirus nanovector for protection against vaginal challenge* PLoS One, **10**: e0119408

28. Survival

Ding, D-C., Chang, Y-C., Liu, H-W. and Chu, T-Y (2011) *Long-term persistence of human papillomavirus in environments* Gynecol. Oncol., **121**, 148–151

29. Transfection

Buck, C.B., Pastrana, D.V., Lowy, D.R. and Schiller, J.T (2005) *Generation of HPV pseudovirions using transfection and their use in neutralization assays* Methods Mol. Med., **119**, 445-462

30. UV radiation

Uberoi, A., Yoshida, S., Frazer, I.H., Pitot, H.C. and Lambert, P.F. (2016) *Role of ultraviolet radiation in papillomavirus-induced disease* PLoS Pathog., **12**: e1005664

31. Vaccines/vaccination

31-1. A7/A9 species groups

Draper, E., Bissett, S.L., Howell-Jones, R., Edwards, D., Munslow, G., Soldan, K. and Beddows, S. (2011) *Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera* Vaccine. **29**, 8585– 8590

31-2. Antibody detection

Nie, J., Huang, W., Wu, X. and Wang, Y. (2014) *Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons* J. Med. Virol., **86**, 1542–1555

31-3. Antibody neutralization assay

Brady, A.M., Unger, E.R. and Panicker, G. (2017) *Description of a novel multiplex avidity assay for evaluating HPV antibodies* J. Immunol. Meth., **447**, 31–36

Guan, J., Bywaters, S.M., Brendle, S.A., Lee, H., Ashley, R.E., Makhov, A.M., Conway, J.F., Christensen, N.D. and Hafenstein, S. (2015) *Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization* Virology, **483**, 253–263

Panicker, G., Rajbhandari, I., Gurbaxani, B.M., Querec, T.D. and Unger, E.R. (2015) *Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types* J. Immunol. Methods, **417**, 107–114

Schellenbacher, C., Shafti-Keramat, S., Huber, B., Fink, D., Brandt, S. and Kirnbauer, R. (2015) *Establishment of an in vitro equine papillomavirus type2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors* Virology, **486**, 284–290 **(E)**

Sehr, P., Rubio, I., Seitz, H., Putzker, K., Ribeiro-Müller, L., Pawlita, M. and Müller, M. (2013) *High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses* PLoS One, **8**: e75677

31-4. Calreticulin

Kim, D., Gambhira, R., Karanam, B., Monie, A., Hung, C-F., Roden, R. and Wu, T-C. (2008) *Generation and characterization of a preventative and therapeutic HPV DNA vaccine* Vaccine, **26**, 351-360

31-5. Capsid variants

Bissett, S.L., Godi, A., Fleury, M.J.J., Touze, A., Cocuzza, C. and Beddows, S. (2015) *Naturally occurring capsid protein variants of human papillomavirus genotype 31 represent a single L1 serotype* J. Virol., **89**, 7748-7757

Mejia, A.F., Culp, T.D., Cladel, N.M., Balogh, K.K., Budgeon, L.R., Buck, C.B. and Christensen, N.D. (2006) *Preclinical Model To Test Human Papillomavirus Virus (HPV) Capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles* J. Virol., **80**, 12393-12397 **(CTR)**

31-6. Capsomer vaccines

Wu, W-H., Gersch, E., Kwak, K., Jagu, S., Karanam, B., Huh, W.K., Garcea, R.L. and Roden, R.B.R. (2011) *Capsomer vaccines protect mice from vaginal challenge with human papillomavirus* PLoS One **6**: e27141

31-7. DNA vaccines

Graham, B.S., Kines, R.C., Corbett, K.S., Nicewonger, J., Johnson, T.R., Chen, M., LaVigne, D., Roberts, J.N., Cuburu. N., Schiller, J.T. and Buck, C.B. (2010) *Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination* Mucosal Immunol., **5**, 475-486

Kines, R.C., Zarnitsyn, V., Johnson, T.R., Pang, Y-Y.S., Corbett, K.S., Nicewonger, J.D., Gangopadhyay, A., Chen, M. et al (2015) *Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles* PLoS One, **10**: e0120797

Peng, S., Monie, A., Kang, T.H., Hung, C-F., Roden, R. and Wu, T-C. (2010) *Efficient delivery of DNA vaccines using human papillomavirus pseudovirions* Gene Ther., **17**, 1453–1464

Yang, B., Yang, A., Peng, S., Pang, X., Roden, R.B.S., Wu, T-C. and Hung, C-F. (2015) *Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination* Cell Biosci., **5**:35

31-8. E2 epitopes

Qian, J., Dong, Y., Pang, Y-Y.s., Ibrahim, R., Berzofsky, J.A., Schiller, J.T. and Kheif, S.N. (2006) *Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice* Int. J. Cancer, **118**, 3022-3029

31-9. Fusion protein

Karanam, B., Gambhira, R., Peng, S.,Jagu, S., Kim, D.J., Ketner, G.W., Stern, P.L., Adams, R.J. and Roden, R.B.S. (2009) *Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity* Vaccine **27**, 1040–1049

31-10. Gardasil®

Han, J.E., Kim, H.K., Park, S.A., Lee, S.J., Kim, H.J., Son, G.H., Kim, Y.T., Cho, Y.J., Kim, H-J. and Lee, N.G. (2010) *A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil® HPV vaccine in mice* Int. Immunopharmacol., **10**, 169-176

31-11. Immunity and immune responses

Giannini, S.L., Hanon, E., Moris, P., Van Mechelen, M., Morel, S., Dessy, F., Fourneau, M.A., Colau, B., Suzich, J., Losonsky, G., Martin, M-T., Dubin, G. and Wettendorf, M.A. (2006) *Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only* Vaccine, **24**, 5937-5949

Han, J.E., Kim, H.K., Park, S.A., Lee, S.J., Kim, H.J., Son, G.H., Kim, Y.T., Cho, Y.J., Kim, H-J. and Lee, N.G. (2010) *A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil® HPV vaccine in mice* Int. Immunopharmacol., **10**, 169-176

Handisurya, A., Day, P.M., Thompson, C.D., Bonelli, M., Lowy, D.R. and Schiller, J.T. (2014) *Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1* PLoS Pathog., **10**: e1004314 **(M)**

Hassett, K.J., Meinerz, N.M., Semmelmann, F., Cousins, M.C., Garcea, R.L. and Randolph, T.W. (2015) *Development of a highly thermostable, adjuvanted human papillomavirus vaccine* Eur. J. Pharm. Biopharm., **94**, 220–228

Huo, Z., Bissett, S.L., Giemza, R., Beddows, S., Oeser, C. and Lewis, D.J.M. (2012) *Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers* PLoS One, **7**: e33736

Kim, H.J., Lim, S.J., Kwag, H-L. and Kim, H-J. (2012) *The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles* PLoS One **7**: e35893

Peng, S., Ma, B., Chen, S-H., Hung, C-F. and Wu, T.C. (2011) *DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific $CD8^+$ T cell immunity* Cell Biosci., **1**: 26

Tam, J.C.H., Bidgood, S.R., McEwan, W.A. and James, L.C. (2014) *Intracellular sensing of complement C3 activates cell autonomous immunity* Science, **345**: 1256070

Vinzón, S.E., Braspenning-Wesch, I., Müller, M., Geissler, E.K., Nindl, I., Gröne, H-J., Schäfer, K. and Rösl, F. (2014) *Protective vaccination against papillomavirus-induced skin tumors under immuno-competent and immunosuppressive conditions: a preclinical study using a natural outbred animal model* PLoS Pathog., **10**: e1003924

31-12. Immunoassay

Panicker, G., Rajbhandari, I and Unger, E. (2012) *Detection of antibodies to HPV vaccine types using a multiplexed immunoassay* FASEB J., **26**, 577.8

Panicker, G., Rajbhandari, I., Gurbaxani, B.M., Querec, T.D. and Unger, E.R. (2015) *Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types* J. Immunol. Methods, **417**, 107–114

31-13. Immunogenicity enhancement

Cho, H., Lee, H-J., Heo, Y-K., Cho, Y., Gwon, Y-D., Kim, M-G., Park, K.H., Oh, Y-K. and Kim, Y.B. (2014) *Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine* PLoS One, **9**: e95961

Chang, D.Y., Kim, H.J. and Kim, H-J. (2012) *Effects of downstream processing on structural integrity and immunogenicity in the manufacture of papillomavirus type 16 L1 virus-like particles* Biotechnol. Bioproc. Eng., **17**, 755-763

Lee, H-J., Hur, Y-K., Cho, Y-D., Kim, M-G., Lee, H-T., Oh, Y-K. and Kim, Y.B. (2012) *Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs* PLoS One, **7**: e50296

Nieto, K., Weghofer, M., Sehr, P., Ritter, M., Sedlmeier, S., Karanam, B., Seitz, H., Müller, M., Kellner, M., Hörer, M., Michaelis, U., Roden, R.B.S,, Gissmann, L., Kleinschmidt, J.A. (2012) *Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate* PLoS One, **7**: e39741

Schellenbacher, C., Roden, R. and Kirnbauer, R. (2009) *Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines* J. Virol., **83**, 10085-10095

31-14. L1 antibodies

Baud, D., Ponci, F., Bobst, M., De Gandhi, P. and Nardelli-Haefliger, D. (2004) *Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1* J. Virol., **78**, 12901-12909

Berg, M.G., Adams, R.J., Gambhira, R., Siracusa, M.C., Scott, A.L., Roden, R.B.S. and Ketner, G. (2014) *Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine* Clin. Vaccine Immunol., **21**, 1224–1231 **(MQ)**

Bissett, S.L., Godi, A., Fleury, M.J.J., Touze, A., Cocuzza, C. and Beddows, S. (2015) *Naturally occurring capsid protein variants of human papillomavirus genotype 31 represent a single L1 serotype* J. Virol., **89**, 7748-7757

Fraillery, D., Zosso, N. and Nardelli-Haefliger, D (2009) *Rectal and vaginal immunization of mice with human papillomavirus L1virus-like particles* Vaccine, **27**. 2326–2334

Qian, J., Dong, Y., Pang, Y-Y.s., Ibrahim, R., Berzofsky, J.A., Schiller, J.T. and Kheif, S.N. (2006) *Combined prophylactic and therapeutic cancer vaccine: Enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice* Int. J. Cancer, **118**, 3022-3029

Rao, N.H., Babu, P.B., Rajendra, L.., Sriraman, R., Pang, Y-Y.S., Schiller, J.T. and Srinivasan, V.A. (2011) *Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles* Vaccine, **29**, 7326– 7334

Yang, B., Yang, A., Peng, S., Pang, X., Roden, R.B.S., Wu, T-C. and Hung, C-F. (2015) *Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination* Cell Biosci., **5**:35

31-15. L2 antibodies

Conway, M.J., Cruz, L., Alam, S., Christensen, N.D., and Meyers, C. (2011) *Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes* PloS One **6**: e16405

Jagu, S., Malandro, N., Kwak, K., Yuan, H., Schlegel, R., Palmer, K.E., Huh, W.K., Campo, M.S. and Roden, R.B.S. (2011) *A multimeric L2 vaccine for prevention of animal papillomavirus infections* Virology, **420**, 43–50 **(C, B)**

Jagu, S., Kwak, K., Schiller, J.T., Lowy, D.R., Kleanthous, H., Kalnin, K., Wang, C., Wang, H-K., Chow, L.T., Huh, W.K., Jaganathan, K.S., Chivukula, S.V. and Roden, R.B.S. (2013) *Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine* J. Virol., **87**, 6127–6136

Jagu, S., Karanam, B., Wang, J.W., Zayed, H., Weghofer, M., Brendle, S.A., Balogh, K.K., Tossi, K.P., Roden, R.B.S. and Christensen, N.D. (2015) *Durable immunity to oncogenic human papillomaviruses elicitedby adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17–36 epitopes* Vaccine 33 (2015) 5553–5563
Kwak, K., Jiang, R., Wang, J.W., Jagu, S., Kirnbauer, R. and Roden, R.B.S. (2014) *Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types* PLoS One, **9**: e97232
Longet, S., Schiller, J.T., Bobst, M., Jichlinski, P. and Nardelli-Haefliger, D. (2011) *A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection* J. Virol., **85**, 13253–13259
Seitz, H., Schmitt, M., Böhmer, G., Kopp-Schneider, A. and Müller, M. (2013) *Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2* Int. J. Cancer, **132**, E139–E148
Yang, B., Yang, A., Peng, S., Pang, X., Roden, R.B.S., Wu, T-C. and Hung, C-F. (2015) *Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination* Cell Biosci., **5**:35
Yoon, S-W., Lee, T-Y., Kim, S-J., Lee, I-H., Sung, M-H., Park, J-S. and Poo, H. (2012) *Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice* Vaccine, **30**, 3286– 3294

31-16. LPS-derivative (non-toxic)

Han, J.E., Kim, H.K., Park, S.A., Lee, S.J., Kim, H.J., Son, G.H., Kim, Y.T., Cho, Y.J., Kim, H-J. and Lee, N.G. (2010) *A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil® HPV vaccine in mice* Int. Immunopharmacol., **10**, 169-176

31-17. Measles-vectored vaccine

Gupta, G., Giannino, V., Rishi, N. and Glueck, R. (2016) *Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine* Vaccine, **34**, 4724–4731

31-18. Memory B cells

Scherer, E.M., Smith, R.A., Simonich, C.A., Niyonzima, N., Carter, J.J. and Galloway, D.A. (2014) *Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity* PLoS Pathog., **10**: e1004461

31-19. MUC1 peptide – VLP conjugate

Pejawar-Gaddy, S., Rajawat, Y., Hilioti, Z., Xue, J., Gaddy, D.F., Finn. O.J., Viscidi, R.P. and Bossis, I. (2010) *Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles* Cancer Immunol. Immunother. **59**, 1685–1696 **(B)**

31-20. Placental malarial antigen

Thrane, S., Janitzek, C.M., Agerbæk, M.O., Ditlev, S.B., Resende, M., Nielsen, M.A., Theander, T.G., Salanti, A. and Sander, A.F. (2015) *A novel virus-like particle based vaccine platform displaying the placental malaria antigen* VAR2CSA PLoS One, **10**: e0143071

31-21. Plants, virus production in

Matić, S., Masenga, V., Poli, A., Rinaldi, R., Milne, R.G., Vecchiati, M. and Noris, E. (2012) *Comparative analysis of recombinant human papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods* Plant Biotechnol. J., **10**, 410–421

31-22. Salmonella-based

Baud, D., Ponci, F., Bobst, M., De Gandhi, P. and Nardelli-Haefliger, D. (2004) *Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1* J. Virol., **78**, 12901-12909
Fraillery, D., Baud, D., Pang, S.Y-Y., Schiller, J., Bobst, M., Zosso, N., Ponci, F. and Nardelli-Haefliger, D. (2007) *Salmonella enterica serovar typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever* Clin. Vaccine Immunol., **14**, 1285-129

31-23. Thermostability

Hassett, K.J., Meinerz, N.M., Semmelmann, F., Cousins, M.C., Garcea, R.L. and Randolph, T.W. (2015) *Development of a highly thermostable, adjuvanted human papillomavirus vaccine* Eur. J. Pharm. Biopharm., **94**, 220–228

31-24. Vaccination status
Grant, B.D., Smith, C.A., Castle, P.E., Scheurer, M.E. and Richards-Kortum, R. (2016) *A paper-based immunoassay to determine HPV vaccination status at the point-of-care* Vaccine, **34**, 5656–5663

31-25. VLP-vaccines
Huber, B., Schellenbacher, C., Jindra, C., Fink, D. Shafti-Keramat, S. Kirnbauer, R. (2015) *A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types* PLoS One, **10**: e0120152

31-26. Yeast-expressed
Kim, S.N., Jeong, H.S., Park, S.N. and Kim, H-J. (2007) *Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae* J. Virol. Methods, **139**, 24-30
Kwag, H-L., Kim, H.J., Chang, D.Y. and Kim, H-J. (2012) *The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae* J. Microbiol., **50**, 813-820

Mini-Review MV05: 5th edition, February 2018

Alere Technologies AS

Axis-Shield Density Gradient Media
is a brand of Alere Technologies AS